Vasopressin antagonists for patients with acute heart failure: Interpreting new clinical and translational data

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 4, 2014, Pages 373-375

  Feldman, A M ^a   Hamad, E ^a   Tsai, E J ^a   Zhu, W ^a   Tilley, D G ^a   Alvarez, R ^a   Cheung, J Y ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIDARESTAT; INOTROPIC AGENT; LIXIVAPTAN; PLACEBO; SODIUM; TOLVAPTAN; VASOPRESSIN ANTAGONIST;

ACUTE HEART FAILURE; ARTICLE; CARDIOVASCULAR MORTALITY; COGNITION; COGNITIVE DEFECT; DRUG MECHANISM; DRUG SAFETY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HUMAN; HYPONATREMIA; PRIORITY JOURNAL; PROGNOSIS; SODIUM BLOOD LEVEL;

ACUTE DISEASE; ANIMALS; ARGININE VASOPRESSIN; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HEART FAILURE; HUMANS; HYPONATREMIA; PROGNOSIS; RECEPTORS, VASOPRESSIN; SODIUM; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84897026353     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.240     Document Type: Article

References (10)

1. Finley, J.J 4th, Konstam, M.A., Udelson, J.E. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 118, 410-421 (2008.
2. Xu, N.; Lixivaptan (review of the BALANCE trial by Cornerstone Therapeutics Presentation to the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Adminstration, 13 September 2012. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM320600.pdf.
3. Li, X et al. Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gaq-mediated cell signaling. Circulation 124, 572-581 (2011.
4. Barr, L.A., Zhu, W., Myers, V.D., Tilley, D.G., Feldman, A.M., Houser, S.R. V1a receptor overexpression in the murine heart depresses the inotropic response to catecholamines. Circulation. 128, A18566 (2013.
5. Lanfear, D.E. et al.; EVEREST trial investigators. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: Insights from the EVEREST trial. Circ. Heart Fail. 6, 47-52 (2013.
6. Zmily, H.D., Alani, A., Ghali, J.K Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment. Expert Opin Drug Metab Toxicol. 9, 645-655 (2013.
7. Cardiokine. Presentation to to the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Adminstration, 13 September 2012. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM320601.pdf.
8. Adams, K.F. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart. J. 149, 209-216 (2005.
9. Fonarow, G.C. et al. Age-And gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). Am. J. Cardiol. 104, 107-115 (2009.
10. Georghiade, M. et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur. Heart J. 28, 980-988 (2007.